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Abstract
The use of stents following angioplasty in ischemic arterial beds is limited by
complications and continuing vascular deterioration. A phenomenon called stent
restenosis post procedure exists which puts patients at a relatively high risk for vessel
stenosis and occlusion 2'3 . Stent restenosis may eventually lead to clinical symptoms such
as myocardial infarction, stroke or limb loss, and if overlooked might lead to death4 .
Within five years of stenting, a significant portion of patients require additional surgical
intervention 5 .
A novel stent-based, implantable, and wireless approach for real-time monitoring
of vessel patency at the site of coronary stents is proposed, will provide a measure of
efficacy of stenting and of the pharmacologic regiment to mitigate the risk of vessel
stenosis and narrowing due to the underlying.
The purpose of this thesis is to explore and test the Hypotheses that there is a
market for a direct, non-invasive monitoring of vessel patency at the site of a
coronary stent; and that an implantable, wireless, stent-based device to monitor
blood flow rate through a coronary stent can be designed and built.
A literature survey of late clinical studies and the opinion of numerous specialist
clinicians collected in interviews and preliminary questionnaire, demonstrate sufficient
clinical ambiguity regarding the safety of coronary stents, including Drug-Eluting Stents
(DES) portrait an underserved clinical need to justify the introduction of a direct, non-
invasive modality for post-op monitoring of vessel patency at the site of a coronary stent.
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A research of existing techniques establishes that measurement techniques are
available for such monitoring. Preliminary results of an in-vitro experiment further
support the proposed approach and lay the foundations for further work.
While not in the scope of this thesis project, additional potential applications for
such an approach are far more reaching than coronary stents and might as well position
this technique as a platform technology for numerous clinical applications.
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1 Introduction
This thesis project is about a potential application of a novel stent-based patency
monitor to the follow-up management of ischemic vascular disease in patients post
angiography and stenting procedure.
The proposed approach is of an implantable device, which will incorporate
multidisciplinary technology and will utilize current clinical knowledge and emerging
technologies such as Micro-Electro-Mechanical Systems (MEMS) and wireless
communication in order to measure in vivo blood flow velocity at the site of a coronary
stent, and communicate data to a wireless, external reading device. The primary purpose
of this device is to facilitate minimally invasive, ongoing monitoring of patency in blood
vessels that have been augmented using angioplasty followed by stenting. The device is
believed to provide a significant improvement in standard of care and quality of life by
allowing earlier diagnosis and thus better end results of related treatment administration.
I have set two Hypotheses to be tested within the scope of this thesis:
1. Hypothesis 1: There is a market for a direct, non-invasive monitoring of
vessel patency at the site of a coronary stent; and
2. Hypothesis 2: An implantable, wireless, stent-based device to monitor blood
flow rate through a coronary stent can be designed and built.
The objectives of this thesis project are therefore two folds:
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1. Assess the significance of the proposed approach, by testing the first Hypothesis
that there is a market for such a device.
Relevant questions will include the following:
a. Is there a need? Is there sufficient clinical ambiguity to justify the
proposed approach?
b. Are physicians interested? Is this interest economically driven or clinically
driven?
c. Would such a device make a difference in outcome by facilitating the real-
time, long-term study and treatment of underlying conditions and vessel
patency? Would such a device be welcomed in the optimization of
management of these conditions?
The first Hypothesis will be tested using the methodologies of a literature survey,
a preliminary questionnaire gauging potential of such approach by medical
specialists, and by framing the value proposition of such an approach.
2. Assess the feasibility of the proposed approach, by testing the second Hypothesis
that such a device can be designed and built.
Relevant questions will include the following:
a. Are measurement techniques available?
b. Design considerations - functionality, biocompatibility
c. Proof of concept
The second Hypothesis will be tested using the methodologies of an overview of
existing technologies, a detailed description of the selected technology and design
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of the proposed device, and by building a proof of concept prototype, and
showing preliminary results of an in-vitro experiment using the prototype.
In order to achieve these objectives, the structure of thesis will be as follows:
Chapter 2 - Background will demonstrate a wide appreciation of the context of the
problem in hand, thus providing motivation to address this problem.
Chapter 3 - Related Work will include a survey and critical assessment of available
techniques, and prior art related to methods for monitoring of stented vessel patency. A
literature review will follow to demonstrate existing controversy regarding the use of
stents.
Chapter 4 - Significance will gauge the clinical need and market characteristics by
showing data and interpretation the results of a clinician preliminary questionnaire.
Chapter 5 -Analysis will describe the proposed novel approach to address the problem in
hand. A theoretical assessment will be followed by practical design and implementation
specifications.
Chapter 6 - Feasibility Assessments will detail the In-vitro Experiment design and
methods followed by an interpretation of preliminary results.
Chapter 7 - Critical assessment of owns work will confront my findings with my
hypotheses, and weigh advantages and disadvantages of the proposed approach.
Chapters 8 - Work Provision will describe risk mitigation and necessary next steps on
the way to commercialization.
Chapter 9 - Summary Conclusions will be followed by Bibliography.
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2 Background
Coronary artery disease affects approximately seven million Americans, causing
1.5M Myocardial Infractions and over half a million deaths per year at an estimated cost
exceeding $100B6 . Coronary artery disease is the result of a complex, years-long process
called Atherosclerosis, in which cellular intimal and mineral additives, fatty and clotting
debris accumulate and deposit in the arterial walls, forming a plaque comprised of cells,
lipids (fats or cholesterol) and fibrous tissue (mostly collagen). This process may lead to
a narrowing of the vessel lumen (stenosis), and reduction of blood flow (ischemia).
Symptoms include angina pectoris (chest pain), and myocardial infarction (heart attack).
In addition, the formed plaque is susceptible to rupture, resulting in an inflammatory
process culminating in thrombus (clot) formation and acute cessation of blood flow to the
heart, and leading to acute coronary syndrome, myocardial infarction, stroke or sudden
death7.
Nearly a million new angioplasty constructions followed by implantation of a
coronary stent - a mechanical device designed to keep the artery open - are performed
every year in the United States in order to treat and overcome arterial stenosis related to
blood vessel diseases (see Table 1 for procedure breakdown)6' 7.
Although such procedures are relatively common and have been proven to save
hundreds of thousands of lives every year, they do not eliminate the underlying
pathophysiology that initially led to arterial stenosis, and pose additional challenges. Post
surgery patients implanted by bare-metal stents are still at a relatively high risk for vessel
stenosis and occlusion at the site of the stent, and in 20-30% of the cases, stenosis persists
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and leads to narrowing and reblocking of the stented artery (stent restenosis) over time
(typically at six-months) ' 5. This occurs due to the body's response to the "controlled
injury" of angioplasty which is characterized by vascular smooth muscle cells migration
into the lumen of the stent and proliferation, thus forming scar tissue which encroaches
on the lumen and forces the stent to close and restrict blood flow in the arteries. Drug-
eluting stents - coated with a thin polymer that slowly releases an antiproliferative drug -
were recently approved for use. While clinical trials assessing the efficacy of drug-eluting
stents after 1 year of patient follow-up have shown encouraging results - reducing the
frequency of vessel retreatment to less than 5%8-18 - it remains unclear whether the drug-
eluting stents are inhibiting or simply delaying restenosis. Ongoing clinical trials of two
dominant drug-coated stents - Johnson & Johnson's Cypher stent19'20 and Boston
Scientific Corp.'s Taxus stent21 - presented new evidence of longer-term blood clots
raising concerns that there is an increase in potentially deadly blood clots in patients'
arteries that have been implanted with drug-coated stents22 23.
Stenosis and blood clotting at the site of the stent may eventually lead to clinical
symptoms such as myocardial infarction, stroke or limb loss, and if overlooked might
lead to death, which raises two major questions - which stent will fail, and how to
monitor the entire post surgery population in a cost effective manner. Nevertheless, the
progress of restenosis as well as the formation of blood clots in these patients is nearly
impossible to monitor with current imaging technologies (see Table 2), consisting of
extremely invasive, costly and risky methods such as Catheter Angiography (CA), or
non-invasive, but extremely expensive tests such as Magnetic Resonance Imaging (MRI)
scan and specifically Coronary Magnetic Resonance Angiography (MRA). For instance,
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MRA fail to provide imaging of vessels containing a stent and often show signal void at
the location of a metallic implant, rendering evaluation of the lumen impossible to
monitor24 25 .
The gold standard treatment therefore remains indirect stress tests of symptomatic
patients only, which if positive, is followed by diagnostic CA26 27. These techniques,
being used selectively and periodically, and being conducted in a stationary setup, results
in a very late diagnosis, if at all, only when the stent is over seventy percent occluded.
Such a high percent of occlusion coupled with late diagnosis place the patient at very
high risk and leads to expensive inefficiencies - all treated patients are administered
extensive long-lasting anti-clotting medications as a preventive mean, and a significant
portion of patients necessitates a repeat procedure or further treatment to reduce blockage
and restore perfusion. These inefficiencies result in extensive burdens, both financial and
clinical, on the health system, such as surveillance direct costs, repeat intervention risks
and caregiver expenses.
Table 1- Statistics on stenting surgeries performed in order to treat and overcome
arterial stenosis related to blood vessel diseases
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Type of Operation Case Load per Stenosis and Comments
Year (US 2004) Occlusion
Angioplasty & Stenting 900,000 20-30% Bare Metal Stents
5% Drug Eluting Stents
Table 2 - Current Diagnostic Methods
For coronary stents current surgical interventions are palliative and do not cure
the underlying disease, leaving the patients highly susceptible to vessel restenosis and
occlusion. Invasive and non-invasive methodologies with improved specificity and
sensitivity are therefore critical for vessel surveillance and subsequent treatment of vessel
stenosis and occlusion.
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Diagnostic Modality Cost per Procedure Comments/Complications
(US$)
Catheter Angiography 5,000 -10,000 * Invasive
* Renal failure
· Bleeding
Magnetic Resonance 2,000 - 4,000 * Poor resolution
Angiography * Poor sensitivity & specificity
Nuclear Imaging 1,000 - 2,000 * Indirect measurement
Duplex Ultrasound 200 - 500 * Insensitive to small vessels
* Physician dependent
May 06
3 Related Art
3.1 Existing Applications
Current surveillance methodologies include broad categories of survey to assess
vessel patency26. In general, these methodologies can be separated into two categories -
DIRCET flow observation by using radiological techniques, that are dangerous,
uncomfortable and invasive; and INDIRECT flow measurements, such as scans, stress
tests etc that infer flow characteristics by watching the reaction of the heart, that are less
specific and less sensitive.
DIRECT - the current most common method of blood flow assessment, Catheter
Angiography (CA), often called Arteriography - which involves skin and arterial
puncture with vessel catheterization by insertion of a thin plastic tube (catheter) into an
artery in the arm or leg, advancement of it into the coronary arteries, and injection of a
dye visible by X-ray into the bloodstream which can then be visible on X-ray pictures - is
highly invasive, with associated long-term risk of renal failure, bleeding, and stroke.
Computed Tomography Angiography (CTA) is a less invasive procedure and
uses small peripheral vein instead of artery for dye injection, but the technology can not
reliably image small, twisted arteries or vessels in rapidly moving organs such as the
heart, and therefore is not readily a substitute for CA.
Nuclear Imaging tests such as Radionuclide Ventriculography or Multiple-Gated
Acquisition Scanning (MUGA), Positron Emission Tomography (PET) or Thallium
Stress test - all involve injecting a radioactive dye into a vein, then using tomographic
imaging to take pictures of the heart as it pumps blood - suffer rapid dissolution of dye,
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require expensive gamma imaging cameras and are able to give a positive result only
above 70% vessel occlusion.
Another invasive technique, referred to as "intravascular ultrasound", where a
miniature ultrasound transducer in inserted by a catheter to monitor blood vessel acoustic
impedance has yet to prove its efficacy.
INDIRECT - Diagnostic Ultrasound or Echocardiography - a safe, painless test,
which gives off a sound wave that bounces off the heart, creating images of its chambers
and valves to examine its structure and motion - has gained popularity in assessing non-
coronary flow velocities but remains insensitive in general to coronary vessels and can
not detect an occlusion less than 50% of vessel lumen.
Magnetic Resonance Imaging (MRI) and specifically Magnetic Resonance
Angiography (MRA) which produces images of flowing blood, became the modality of
choice for angiography due to its non-invasiveness, but suffers low spatial resolution and
is not adequate for diagnosis and treatment planning of small vessels (3 to 4 mm in
diameter) and, in particular, the coronary arteries due to not only their size, but also their
tortuous and complex pathway, the abundant signal from surrounding epicardial fat, and
the significant motion associated with both respiration28' 29 and cardiac motion. In addition
and of special interest for this thesis, a major obstacle for coronary MRA imaging is the
use of intracoronary stents. Although not a contraindication for MRA30, local signal voids
or artifact associated with implanted metallic objects such as intravascular stents preclude
assessment of the stented portion of the vessel31 .
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A stress test, sometimes called a treadmill test or exercise test - which gradually
increases heart demand for oxygen, thus requiring the heart to pump more blood and
revealing coronary insufficiencies - remains the gold standard to assess heart
performance, but is limited in nature for some patients and can subject patients with a
dysfunctional heart to exercise loads and therefore pose additional risk.
Currently employed methodologies are unable to screen the asymptomatic,
general population of post-surgery patients for vessel occlusion. Traditional testing
methods are time consuming, invasive, expensive and associated with risk to patients.
Large groups of post-surgical patients are therefore at risk for clinically silent vessel
occlusion leading to myocardial infarction, loss of limb, stroke and sudden death. In
addition, currently available methodologies are not specialized for frequent blood flow
determinations during the convalescent period. By ignoring the changing physiology of
coronary arteries blood flow, data from current techniques provide static anatomical
measurements and misinterpret physiological, hemodynamic changes seen in these
vessels. A better invention would be capable of monitoring hemodynamic conditions over
extended periods of time to allow dynamic assessment of such changes.
Besides the blood flow measurement mechanism used, other aspects of modem
vessel surveillance and care are non-optimal. Currently employed techniques require
outpatient hospitalization, critical operator expertise and have traditionally been restricted
to cardiac catheterization laboratories and intensive care units (ICUs). Such
measurements can not be made easily in ambulatory settings, or under conditions of
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cardiac loading, such as exercise, and therefore result in inconsistent information. A
better invention would permit simplified, rapid and real-time vessel interrogation.
A preferred arterial flow measurement approach would include: (1) non-invasive
technique, (2) easy deployment of the measuring element (3) efficacy for all types of
coronary stents, and (4) optimal post-surgical assessment and care of the vessel.
3.2 Prior Art
The description herein describes systems and devices for measuring coronary
artery flow rate and arterial blood velocity.
Ohlsson et a132 describe implantation of a pressure sensor and an oxygen sensor,
the IHM-1, Model 10040 (Medtronic, Inc.). However, in this study, 12 out of 21 oxygen
sensors within the first 6 months of implantation failed, probably because sensors were
being coated by fibrous tissue. In addition, surgical implantation of this pacemaker-style
device requires a 2-3 hour procedure in the operating room, which is more costly than a
catheterization procedure to insert a pressure sensor. Data from this study, however,
points to the importance of long-term, continuous pressure monitoring, as opposed to
one-time measurements using standard cardiac catheterization techniques.
In U.S. Pat. No. 6053873: Pressure-sensing stent issued Apr. 25, 2000 to Govari,
Assaf et al, a method of monitoring flow rates within a stent is described. In particular,
the use of ultrasonic sensors to monitor blood flow rates is described. However, due to
the change in composition and thickness of the biological material present on the sensor
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surface, the boundary conditions at the sensor may change over time. Initially, the sensor
surface, which may be calibrated against blood, may become covered with a layer of
thrombus over time. Subsequently, the thrombus will transform into fibrous tissue,
affecting the absorption of the ultrasound signal. Blood may have an ultrasound
absorption level similar to water, of around 0.002 dB/MHz cm, while the fibrous tissue
layer may have an absorption level similar to muscle, of around 2 dB/MHz cm. Thus,
such a sensor may require periodic re-calibration. Unfortunately, the re-calibration
process requires an invasive cardiac catheterization procedure, in which flow rates are
determined using ultrasound, Thermodilution, or the Fick method. In order to avoid
additional interventional procedures, a fouling-resistant approach may be valuable.
Another approach to the use of pressure sensors to quantify pulsatile flow in
vessel is disclosed in U.S. Pat. No. 6237398: System and method for monitoring
pressure, flow and constriction parameters of plumbing and blood vessels issued
May 29, 2001 to Porat, Yariv, et al. - two spaced pressure sensors are attached to inner
walls of blood vessel for recording pressure records based on which is pulsatile flow
quantified. It has been shown that variations in intraluminal pressure is being
compensated for by the body in the means of change of flow rate, leading to not getting a
measurable, significant pressure drop only until approximately 70 percent of the vessel is
occluded5 °. Therefore, measuring pressure might not be the best approach to monitor
subtle changes in vessel patency to be able to fine tune post procedure treatment regimen.
Another method of ultrasonic Doppler monitoring of blood flow in a blood vessel is
disclosed in U.S. Pat. No. 5289821: Method of ultrasonic Doppler monitoring of
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blood flow in a blood vessel issued Mar. 1, 1994 to Swartz, William M., where an
ultrasonic transducer-conducer wire assembly is removably attached to non-removable
cuff around vessel, to monitor blood flow within the blood vessel. After completion of
monitoring the ultrasonic transducer-wire assembly, but not the cuff are removed from
the patient. This method is clearly highly invasive and allows monitoring of blood flow
during the procedure only.
In U.S. Pat. No. 6729336: In-stent restenosis detection issued May 4, 2004 to
Da Silva, Luiz B., et al., an apparatus is described which can presumably be used to
detect in stent restenosis by comprising an acoustic sensor to detect stent acoustic
oscillations. In U.S. Pat. No. 6308715: Ultrasonic detection of restenosis in stents
issued Oct. 30, 2001 to Weissman, Eric M., et al., a diagnosing method is described
which utilizes a similar concept of exciting the stent structure to produce acoustic signal
indicative of the diagnosis. The acoustic signal is then analyzed to predict a degree of
restenosis experienced by the stent. In both methods disclosed, ultrasonic waves are used
to assess INDIRECTLY the level of stenosis within the stent, by predicting material
composition and the thickness of the wall around the stent rather than to assess blood
flow velocity. Such an indirect approach can only assist estimating the vessel patency and
is not complete - material composition, as well as wall thickness, might present
asymmetric patterns which make it nearly impossible to accurately assess. In addition,
exciting an intraluminal acoustic vibration at a site of potential stenosis might pose
additional risk of plaque rapture and thrombosis.
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In U.S. Pat. No. 6309350: Pressure/temperature/monitor device for heart
implantation issued Oct. 30, 2001 to VanTassel, Robert A., et al., a sensor is described
which is anchored in the wall of the heart, or in a blood vessel. However, no mention is
made of the difficulty with sensor fouling due to thrombus formation, or how to
compensate for that. Pressure sensors would require recalibration as the softer thrombus
transforms into neointimal tissue, or as the thickness of the encapsulating tissue layer
changes. While the device could be initially calibrated during implantation, it would need
to be recalibrated over time. Because recalibration requires an invasive cardiac
catheterization procedure, it would be desirable to avoid this if at all possible.
In addition, VanTassel et al. suggest the use of standard Thermodilution methods to
determine flow rates. Thermodilution is normally performed by injection of either room
temperature or iced saline through a catheter. However, it is desirable to avoid re-
interventions if possible. Therefore, standard Thermodilution methods are less desirable
than the current invention. In addition, it is impractical to use the sensor in the standard
method, i.e., by locally cooling the blood, because chilling units are impractically large
for implantation as a sensor. Further, Thermodilution methods would be inaccurate if a
relatively thick layer of cells covered the thermocouple or sensing element. This would
be especially true if only a small temperature rise were introduced into a large volume of
flowing blood, such as in the pulmonary artery. Larger temperature rises (>2.5.degree.
C.) would cause local tissue damage.
Another approach of Thermodilution is disclosed in U.S. Pat. No. 5598847:
Implantable flow sensor apparatus and method issued Feb. 4, 1997 to Renger,
Herman L., where a pyroelectric sensor in a rigid cylindrical tube is implanted
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intraluminally to measure the resultant temperature change of blood, produced by a
heater, to indicate the blood flow rate through the blood vessel or artery. By using a rigid
tube this approach suffers several drawbacks - a rigid tube may limit the device usage, by
constraining its deliverability by a catheter, limiting the treated arteries to ones with a
relatively larger diameter. A rigid structure may infringe vessel elasticity and induce
friction or irritation of surrounding tissues, such as the vessel endothelium, the
epicardium, and the visceral layer of the pericardium. It may also increase the long-term
risk of thrombosis along the tube. In addition, the amount of energy required to
significantly increase the blood volume that flows through the tube to a measurable levels
is higher to allow an external induction in physiological conditions.
In U.S. Pat. No. 5271408: Hydrodynamic system for blood flow measurement
issued Dec. 21, 1993 to Breyer, Branko, et al., a hydrodynamic system for blood flow
measurement is disclosed - two spaced passive transducers are mounted at the exterior
surface of a catheter implanted within the vascular vessel, the first with a protrusion in
the form of a hydrofoil profile, and the other with a flat surface at the exterior of the
catheter. The transducer having the hydrofoil profile generates a signal due to the quasi-
static pressure acting on the transducer as well as due to the drag force acting on the
transducer caused by the blood flow. The other transducer generates a signal solely due to
the quasi-static pressure; their respective signals can be subtracted in a differential
amplifier, so that a signal proportional to the axial flow velocity is obtained. The insertion
of the catheter into the vessel lumen for a long term period, as well as the transducers
required interactability with the blood flow, pose a significant risk of thrombosis
formation on the catheter or transducers' surfaces, and makes its long-term functionality
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questionable after transducers' surface is coated by endothelium or restenosis.
Notwithstanding the extensive efforts in the prior art, however, there remains a
need for an implantable blood velocity/flow sensor, which can provide useful flow
measurements for an extended period of time, without material interference from
thrombus formation, embolization, or other foreign body response. Preferably, the sensor
is capable of continuous or near continuous monitoring, making data available to the
patient or medical personnel.
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4 Significance
4.1 Literature Survey
A novel method for treating coronary artery stenosis, termed Percutaneous
Transluminal Coronary Angioplasty (PTCA), commonly called balloon angioplasty, was
introduced in 1977 by Dr. AndreasGruentzig (Switzerland), which can be performed
using minimally invasive catheter procedure. In PTCA, the occluding plaque is
compressed by the inflated balloon while no material is removed, and vessel patency is
restored. Although the successful opening of the artery, in a small percentage of cases,
the artery would collapse immediately after the balloon was deflated, requiring an
emergency bypass graft surgery to repair the problem. In addition, in about one-third of
cases, re-narrowing of the treated segment (restenosis) may occur in the immediate six
months period post procedure, necessitating a repeat procedure or an invasive coronary
artery bypass surgery. Despite intensive research effort and several drug trials, a solution
to this phenomenon remains elusive33'34 .
In order to reduce restenosis rates and maintain vessel patency, a device called a
stent - a metal tube or "scaffold", mounted on the balloon and able to be opened once
inside the coronary artery - was first inserted into a human coronary artery in 1986, in
Toulouse, France, by Drs. Jacques Puel and Ulrich Sigwart. In 1994 the first Palmaz-
Schatz stent was approved for use in the United States. Over the next decade, several
generations of bare metal stents were developed, with each succeeding one being more
flexible and easier to deliver to the narrowing. But while bare metal stents nearly
eliminated acute artery occlusion post procedure, in about 25% of cases restenosis
persisted and occlusion at the treated site occurs, typically at six-month post
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procedure33'3 4. It was learned that restenosis, was not only the sole result of the coronary
artery disease, but rather was the recurrence of the underlying disease combined with the
body's response to the "controlled injury" of angioplasty, characterized by growth of
smooth muscle cells roughly analogous to a scar forming over an injury.
New research efforts moved away from the purely mechanical bare metal stents
and toward pharmacologic advances of a variety of drugs targeted at interrupting the
biological processes that caused restenosis. Drug-eluting stent - first introduced in 2003 -
incorporate a normal metal stent which is being coated with a pharmacologic agent (drug)
which is sometimes imbedded in a thin polymer for time-release3 53 6
Currently two drug-eluting stents have received FDA approval for sale in the
United States as well as the CE mark for sale in Europe - the Cordis CYPHERTM
sirolimus-eluting stent in April 2003 (which later became Johnson & Johnson's product),
and the Boston Scientific TAXUSTM paclitaxel-eluting stent in March 2004. Medtronic's
Endeavor stent which uses ABT-578, a drug made by Abbott, was approved in Europe in
April 2005. Additional drug-eluting stents - Abbott's own Zomaxx stent and Guidant's
Xience stent - are currently undergoing clinical trials.
But while in recent clinical trials drug-eluting stents have been extremely
successful in reducing restenosis - both the TAXUSTM and CYPHERTM stents have
shown significant reduction of restenosis from the 20-30% range to single digits, and also
a dramatic reduction in reinterventions in diabetics, a population that has been highly
susceptible to restenosis in the past8-' 8 - leading market analysts to predict that the current
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world market for drug-eluting stents will double to $5 billion annually, new concern
arise. It still remains unclear whether the drug-eluting stents are inhibiting or simply
delaying restenosis 9'223. In addition, the issue of stent thrombosis is being scrutinized
and concerns have been raised regarding an increase in potentially deadly blood clots in
patients' arteries that have been implanted with drug-coated stents - In October 2003, the
FDA issued a warning regarding cases of Sub-Acute Thrombosis (SAT or blood clotting)
with the CYPHERTM stent that resulted in some deaths20. Ongoing clinical trial of the
CYPHERTM stent and the TAXUSTM stent have suggested an increase in the incidence of
late stent thrombosis in patients implanted with drug-eluting stents, where the blood-
clotting inside the stent can occur one or more years post-stenting. While this has been
seen rarely in both the TAXUSTM and CYPHERTM stent trials, thrombosis is extremely
dangerous, fatal in over one-third of cases.
To prevent thrombosis, patients are being administered a long-term antiplatelet
therapy post-stenting to prevent the blood from reacting to the new device by thickening
and clogging up the newly expanded artery and to allow a smooth, thin layer of
endothelial cells to grow over the stent during this period, thus reducing the tendency for
clotting. The therapy consists of anti-clotting or antiplatelet drugs such as aspirin,
clopidogrel (Plavix) or ticlopidine (Ticlid) for six or more months after the stenting37 38.
New stent designs exist but have yet to demonstrate a superior outcome in relation
with restenosis and thrombosis. An example is the Conor MedSystems' CoStar stent
which was approved in Europe in February 2006 - by utilizing a bioresorbable polymer to
deliver the anti-restenosis drug, the CoStar stent, after eluting drug for a few months,
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becomes in effect a bare metal stent - which may eliminate the concern of late stent
thrombosis present in permanent polymer stents. In addition, Germany-based Biotronik is
testing a completely bioabsorable stent which will totally disappear after its role is
fulfilled.
In addition to susceptibility to restenosis and thrombosis, literature suggests that
several decisions made by the interventional cardiologist are of equal importance, and
have been shown to have high correlation with the procedure clinical outcome post
stenting27 - the correct sizing of the stent, both length-wise to match the length of the
lesion, and diameter-wise to match the artery lumen are two of these decisions and can be
considered and determined prior to the procedure itself to ensure best result. Sufficient
deployment of the stent, however, is equally crucial and must be evaluated in real time
during the procedure. The physician has to verify that the stent, once optimally placed at
the stenosis site, is expanded fully to the arterial wall - under-expansion can result in
small gaps between the stent and arterial wall which can lead to serious complications
such as blood clots, or Sub-Acute Thrombosis (SAT). Such assessments of stent
expansion are made by viewing the real-time angiogram in the cath lab. Intravascular
ultrasound imaging might provide more detailed information, but due to this technique
operational complexity it is nearly never being utilized. Direct, easy-to-use
methodologies for monitoring vessel patency during and immediately post stent
deployment are therefore necessary to improve procedure outcome.
4.2 Preliminary Questionnaire
4.2.1 Overview
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Ten specialist clinicians27 were approached with a preliminary questionnaire (see
Figure 1) followed by a face-to-face interview to assess the clinical need and gauge the
potential market for the proposed approach to of a Novel Stent-based Patency Monitor to
the management of Ischemic Vascular Disease.
To avoid any potential bias, no information was delivered to the clinician prior to
questionnaire filling (such as the purpose of the questionnaire, the proposed approach, or
any other subjective evaluation of clinical conditions and standard of care).
4.2.2 Materials and Method
Clinical Need
To define the nature and scope of the clinical need, clinicians were asked the
following two questions:
1. What is the main post-op risk associated with patients who undergo a coronary
angioplasty and Stenting procedure? What is the symptom/complication
prevalence?
This question intended to assess whether there is a status-queue in the medical
community or are different specialists present different perspectives regarding the risk
associated with such procedures. By asking of the prevalence, a second insight was
gained regarding the awareness of such a risk within the medical community.
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2. How do you follow-up these patients to avoid/detect this symptom/complication?
In this question physicians were asked to fill relevant screening modalities,
medications and other modalities and to quote the frequency of post procedure follow-up
visits, to gauge existing standards of care two folds - the first being to assess whether
sufficient screening and interventions exist to mitigate the previously described risk and
overcome its clinical outcomes, the second being to evaluate if existing imaging
applications fulfill the clinical need associated with that risk.
Relatively similar inputs in response to these questions with high correlation to
literature data would suggest a well-defined need with high awareness, whereas higher
spread would suggest the contrary.
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Physician Interest
To find out if physicians were at all interested in improving the current clinical
status, and if so what drives this interest, clinicians were asked the following two
questions:
3. If you had the ability to monitor a single parameter in these patients as part of
the follow-up, in a non-invasive, instantaneous screening procedure which
could be performed in an office or a clinic, what would you monitor?
In this question physicians were asked to circle the most indicative parameter of
clinical significance for the symptom/complication from the following blood
characteristics:
a. Systolic Pressure within the stent
b. Diastolic Pressure within the stent
c. Flow Rate (Volume/Time) through the stent
d. Flow Velocity through the stent
e. Hematocrit Level
f. Blood Viscosity
g. Blood Conductivity
h. Specific Enzyme Levels
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This question intended to define a clinician interest in monitoring a specific blood
character of clinical significance - to find if there is indeed a wide spread, common
interest that can be addressed.
4. If you had the ability to detect significant change within a stent of this
parameter, at a simple, office-based screening procedure, would that affect the
follow-up regimen and how?
In this question physicians were asked to specify if such monitoring process
would or would not affect the follow-up treatment and how - as an insight to whether or
not they would welcome utilization of such approach and the associated paradigm shift
for follow-up vessel patency monitoring.
Physician inputs in response to these questions will reveal whether there is a
strong, unified interest in monitoring a single, most significant character, and will help
estimate their openness and potential acceptance of a modality that would address this
interest, if exists.
Change in Clinical Outcome
To find out if physicians believe, based on current available clinical information
and best practice, that the use of such monitoring might change clinical outcome,
clinicians were asked the following question:
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5. Do you believe such monitoring and sequential adjusted treatment can change
the clinical outcome of these patients?
Physician inputs in response to this question will help understand the perceived
value associated with such monitoring process.
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Ciican Qsiomai' - Jnuay 2006
Clinician Name:
1. What is the main post-op risk associated withpatients who undergo a coronary angioplasty and
Stenting procedure? What is the synptoircomplication prevalence?
2. -Howdo you follow-up these patients to avoiddetect this srmtomlcomplication? (fill relevant)
a. Screening:
b.. Medications
Mudality Frequeny(examsr)
An oglaphyArtenogaphy
ComputedTomograph Agogrmph (TA)
Magnetic Resonnce Angiography RA)
'Duplex Ultrsound 
DrugName Dosage aiFrequecy
c. Outpatient visits -Frequency
d. Other
3. If you.had the ability to monitor a single parameter in these patients .as pat'ofthe follow-up, in
a non-irnvasive, instantaneous screening procedure which could be performed in an office or a
clinic, what would you monitor? (circle .the most indicative parameter of clinical significance
for the symptomcomplication in q.1)
a. Systolic Pressure withinthe stert
b. Diastolic Pressure within the stent
c. .FlowRatethrough the stert
d. Flow Volume through the stent
e. Hematocrit Level
f. Blood Viscosity
g. Blood Cnductivity:
h. Specific Eryme Levels
4.: If you had the ability to'detect sigificant .change within a stent of this parameter, at .a simple,
offie-based screening procedure, would :that afFect the follow-up regimen-and how?
a. .Yes (please explain)
b. No (please explain)
5. Do you believe such monitoring and sequential adjusted treatment can change the clinical
outcome of these patients? 
Thank you!
Figure 1 - Clinician Questionnaire
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4.2.3 Results
Question 1
All clinicians stated stent restenosis and SAT as the leading post-op
complications.
Clinicians specified the prevalence of restenosis to range from 4% to 15% in DES
and 20% to 30% in bare metal stents, while in literature the estimated prevalence of drug-
eluting stent (DES) is 5-10% and of bare metal stent is 20%-30%.
Acute Thrombosis was mentioned as another serious complication, which while is
much less prevalent, is associated with much more severe outcome, with approximately
40% mortality AND >80% acute MI. Clinicians specified the prevalence of SAT to be 1-
2%, while in literature the estimated prevalence of SAT is 1%.
Clinicians stated to be using DES in 80-90% of cases.
Question 2
Screening - for asymptomatic patients no screening methodology is undertaken
at post-op follow-up. This finding is somewhat surprising, but sits in agreement with the
technical deficiency of current modalities to image patency of stented vessels.
When patients become symptomatic with angina a stress test is performed, which
if positive leads to either an Angiography or a CTA test, to evaluate restenosis progress.
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For SAT, as it is an acute event, no screening modality is available.
Medications - patients are unanimously administered anticoagulative drugs such
as Aspirin (325mg QD), Plavix (75mg QD), CHOL, or BP Rx.
Frequency of Outpatient Visits - patients are followed-up, in general, by an
outpatient visit to the interventional cardiologist two weeks post procedure and 2-4
additional visits per year thereafter. These visits are conducted regardless of additional,
parallel visits to PCPs and cardiologists.
Question 3
All clinicians selected Flow Rate through the stent as the most clinically
significant parameter indicative of vessel patency and stent underlying restenosis
conditions, which would be their first choice if were able to monitor as part of the follow-
up.
Question 4
All clinicians but one answered Yes believing that monitoring Flow Rate through
the stent may change the follow-up regimen. In their aggregated view, it would provide
better information than stress test does, and might increase the frequency of follow-up
visits and stress tests, while at the same time might reduce the need for angiography
testing and augment its results when done, and facilitate earlier reintervention if so
required.
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One clinician answered No claiming that as no effective medications exist to
prevent restenosis, such monitoring, while has the potential to diagnose asymptomatic
patients and facilitate earlier reintervention, would not change the medication
administration.
Question 5
Half of clinicians answered Yes believing that monitoring vessel patency on its
own has the potential to improve clinical outcome by better understanding the disease
progress and responding accordingly.
The other half was uncertain, stating that there is lack of knowledge to estimate
the potential outcome, and that the superiority of such approach relative to a stress test is
yet to be proven.
In addition to these five questions, clinicians specified an additional complication
when there is an incomplete expansion of the stent during deployment, which requires
immediate reintervention. There is no screening modality to detect such event except for
intra-vascular ultrasound immediately post procedure which is rarely used due to its
cumbersome operation.
All clinicians showed great interest in such a technology, stated that if such
technology existed they would used it on all of their patients, and asked to be followed-up
with the progress of this project.
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4.3 Interpretation of results
The literature survey reveals the existence of vibrant controversy regarding the
safety and effectiveness of DES in preventing restenosis - clinical studies have been
performed for relatively short periods of no more than two years, and the findings are still
eluded. It is yet to been proven that DES actually prevent restenosis rather than delay it.
New evidence of higher risk of thrombosis when DES is used further fuel the debate
within the medical community.
The results obtained in the preliminary questionnaire, clearly suggest that there
exist a clinical need to monitor vessel patency post-op. The survey results suggest that
clinicians are highly aware of the existence and prevalence of restenosis and thrombosis
which suggest that this need is well defined and accepted.
Current modalities are not sufficient for such broad monitoring process, and due
to multiple reasons are rarely, if at all, utilized for such objective.
The most important factor indicative of vessel patency and stent underlying
restenosis conditions is synonimally believed to be Flow Rate through the stent.
Monitoring of vessel patency is perceived advantageous in order to accurately detect the
natural history progress of underlying disease, to allow earlier reintervention or regimen
adjustment and reduce complication rate in post-op patients.
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Integrating the results, I believe there is sufficient evidence of clinicians' interest
in a novel approach to address this need. Given that the perceived value added is in
changing current standard of care in what is believed to be an opportunity to improve
clinical outcome, and from the other hand there is minimal utilization of existing
imaging modalities, this interest is likely to be clinically rather than economically driven.
A detailed cost-effective analysis is required to establish economically driven incentives
for the health care system as a whole in utilizing such a novel approach.
According to this preliminary survey, clinicians believe that there may be a
difference in clinical outcome by facilitating a real-time, long-term monitoring of vessel
patency and a real option to better manage post-op follow-up and related treatment.
Therefore, it is reasonable to estimate that a novel approach which while would yet need
to be evaluated in the field, might allow such improvement, would be welcomed in the
optimization of management of these conditions.
4.4 Clinical Need
As described previously, the use of stents following angioplasty in ischemic
arterial beds is limited by complications and continuing vascular deterioration. A
phenomenon called stent restenosis post procedure exists which puts patients at a
relatively high risk for vessel occlusion. Stent restenosis may eventually lead to clinical
symptoms such as myocardial infarction, stroke or limb loss, and if overlooked might
lead to death ' 5.
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Within five years of stenting, a significant portion of patients require additional
surgical intervention. Additional complications result from insufficient stent expansion at
deployment, which in turn can lead to serious complications such as blood clots, or Sub-
Acute Thrombosis (SAT)6 7.
Post procedural assessment of vessel patency at the site of a stent is therefore
critical to optimal post-operative outcome.
Based on the literature survey and the results of the preliminary physician survey,
it is reasonable to estimate that the most significant factor clinically to monitor vessel
patency at the site of a stent would be blood flow rate, meaning the volume of blood
transferred through the stent lumen in a time constant. In clinical settings, the most
common flow rate unit used is cc/min, although other flow rate units such as cc/hr are in
use as well.
In an optimal case where the vessel cross-sectional area is known and remains
constant along time, blood flow rate can be determined inferentially by retrieving the
blood average velocity. In such case blood velocity depends nearly entirely on the
pressure differential that is forcing the blood through the vessel, and either direct fluid
velocity or indirect pressure differential along a known distance would allow flow rate
assessment.
In real life scenarios, however, and especially for our interest, vessel cross-
sectional area in patients suffering from a vascular disease deteriorate over time due to
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restenosis and therefore average velocity or pressure differential alone are not sufficient
and more information is required to assess flow rate.
Additional factors that affect blood flow rate include the blood viscosity and
density. These factors tend to remain constant in most physiological conditions with only
minor fluctuations.
A device that will allow a real time measure of efficacy of stenting and
pharmacologic regiment is therefore required, to mitigate the risk of vessel restenosis and
occlusion due to the underlying disease and the body reaction to the controlled injury at
the site of stenting.
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5 Analysis
5.1 Available Techniques
Several techniques are available to be used in flowmeters, which might be
candidates for DIRECT non-invasive monitoring of vessel patency. In general, these
techniques can be classified as either differential pressure sensors or velocity sensors39 42.
Less common techniques include laser or light flowmeters and hydrodynamic
flowmeters.
Differential pressure devices4 3
The basic operating principle of differential pressure flowmeters is based on the
premise that the pressure drop across the vessel segment is proportional to the square of
the flow rate within that segment. The flow rate is obtained by measuring the pressure
differential and extracting the square root.
Differential pressure flowmeters have a primary and secondary element. The
primary element causes a change in kinetic energy, which creates the differential pressure
in the vessel segment. The secondary element measures the differential pressure and
provides the signal or read-out that is converted to the actual flow value. The sensor must
be properly matched to the vessel size, flow conditions, and the blood properties, and
therefore might require frequent calibration events.
Velocity Sensors
Velocity sensor techniques consist of Electromagnetic, Ultrasonic and
Thermodilution designs.
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Electromagnetic flowmeters4 4 operation is derived from Faraday's law of
electromagnetic induction that states that a voltage will be induced when a conductor
moves through a magnetic field. The blood, being an electrically conductive liquid serves
as the conductor; the magnetic field is generated by either energized coils outside the
vessel or induced from outside the body. Two electrodes mounted in opposite sides of the
vessel lumen detect the voltage, which is measured by a secondary element. The amount
of voltage (E) developed across the electrodes will be proportional to the diameter of the
vessel (D), the magnetic field density (B) generated by the coils, and the velocity (V) of
the blood flow:
E=VxBxD
If B and D are known (which in this case will be the distance between the electrodes), the
blood flow velocity V can be easily deduced by measuring E.
The voltage that develops at the electrodes is a millivolt signal. This signal is
typically converted into a standard current (4-20 mA) or frequency output (0-10,000 Hz)
at or near the sensor and then can be converted into a digital output, allowing for wireless
communication with an external reader outside the body.
Magnetic flowmeters expected inaccuracy is from 0.2-1% of rate.
Ultrasonic flowmeters4 5 can be divided into Doppler-shift flowmeters and time-
of-travel (or transit) meters.
Doppler-shift flowmeters measure the frequency shifts caused by blood flow.
Two transducers are attached to one side of the vessel, one of them is a receiver element.
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The transducer sends a signal of known frequency ultrasonic pulse into the blood stream.
Blood particles, such as RBCs, cause the pulse to be reflected to the receiver element.
Because the blood causing the reflection is moving, the frequency of the returned pulse is
shifted. The frequency shift is proportional to the blood velocity. Measurement
inaccuracy ranges from ±1% to ±5%.
laser Doppler flowmeters use the same concept but utilize a coherent, low
powered laser beam, and are therefore more suitable for artificial applications such as
measuring the blood flow within the microcirculatory beds under the skin and less so for
deeper applications such as coronary arteries.
Transit Time flowmeters use wide-beam illumination, and two transducers
mounted on each side of the vessel - one upstream and one downstream - to pass
ultrasonic signals back and forth, alternately intersecting the flowing liquid in the
upstream and downstream directions. The configuration is such that the sound waves
traveling between the devices are at a 45 deg. angle to the direction of blood flow. The
speed of the signal traveling between the transducers increases or decreases with the
direction of transmission. The Flowmeter derives an accurate measure of the 'transit-time'
it took the wave of ultrasound to travel from one transducer to the other. The difference
between the upstream and downstream integrated transit times is a measure of flow
velocity.
Theoretically, transit-time ultrasonic meters are very accurate (inaccuracy of
_0.1% of reading is sometimes claimed).
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These flowmeters can measure two different outputs - Pulsatile, which is the real-
time flow waveform and Mean which gives out a filtered signal of mean flow.
Thermodilution measurement4 6 is performed by sensing temperature gradient of
blood along a specific time period. The initial blood temperature change is produced
either by injection of iced saline through a catheter to locally cool the blood, or by a
heater, to locally heat the blood. A thermocouple or sensing element retrieves the
resultant temperature change of blood, which is indicative of the blood flow rate through
the blood vessel or artery.
5.2 Proposed Approach
5.2.1 Overview
The proposed device is an implantable, wireless sensor, able to measure flow rate
and communicate its retrieved data to an external device. It will be incorporated within a
stent in order to measure blood flow velocity in the stent post angioplasty and stenting
surgery. The device will be adhered to the stent wire mesh and its layout will not infringe
the stent footprint, thus allowing for vascular spontaneous contraction and dilation, while
ensuring mechanical flexibility and fixation to the stent. The device will be attached to
the stent as part of the stent's manufacturing process and will be delivered to the patient's
vascular system together with the stent. The device is a Class III device by the standards
used by the FDA to classify medical devices.
The device will allow a non-invasive, on-demand, and dynamic information about
the blood flow velocity characteristics within the stent. Readings from the device by an
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external reader will be taken frequently, starting during and immediately after the
procedure and continuing during regular PCP (Primary Care Physician) visits, Cath lab
follow up visits, or visits to the cardiac specialist treating the patient. Since normal and
pathological blood flow rates within native and stented arteries are well characterized, the
data obtained from the device will have significant meaning to the physician. By
accurately measuring blood flow velocity in the stent on a long-term, continuous basis,
the device will allow understanding of the flow fluctuations and underlying physiological
changes within the stent post stenting procedure. This information will provide an
opportunity for an early diagnosis and treatment for restenosis, as well as facilitate an
ongoing monitoring to assess the prescribed treatment efficacy. Based on the patterns
observed from the readings, the physician will be able to determine whether a more
invasive and thorough examination is needed before large percent of the stent is
occluded.
The proposed approach is the only one to directly and non-invasively give
ongoing blood flow measurements, and as such, there really is no competing alternative.
5.2.2 Device Requirements
The requirements of such a device consist of both Efficacy issues (Functional
Requirements) and Safety issues (Anatomical, Biological and Physiological
requirements), detailed herein.
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Functional Requirements
1. The device is required to measure absolute flow rate (cc/min) within a stented
vessel at the location of the stent.
2. The device shall be able to measure blood flow 'upon request', meaning while it
is temporarily activated.
3. Each measurement shall be a single assessment of the blood flow rate.
4. The measurement accuracy shall be within 5% of the actual flow rate, in order to
truly reflect blood flow changes over time and be able to correlate with existent
stenosis.
5. The device shall communicate wirelessly with an external reading device to allow
non-invasive blood flow measurement post angioplasty and stenting procedure.
6. The device shall function within the body for an unlimited period of time, without
the need for invasive intervention. Practically, it should function for the entire
longevity of the underlying stent.
Anatomical Requirements
7. The device footprint would be minimal, <0.5mm3 including all subcomponents.
8. The device should not interfere with stent elasticity, to avoid stent kinking and
occlusion due to the device stiffness.
9. The device shall be fixated to the stent, to avoid longitudinal movement along the
blood vessel or complete migration into the pericardial cavity.
10. The device shall not interfere with stent deliverability into target site, to allow
insertion of the stent and adhered device as a single implant with current
procedure methodology and know-how.
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Biological Requirements
11. The device and its components should be biocompatible:
· The device shall not induce any unnatural responses or remodeling of the
surrounding organs, tissues and cells.
* The device shall not induce any toxicity to the surrounding organs, tissues and
cells.
* The device and its components will be made of materials with no short term
irritation or sensitization, no cytotoxicity, no acute systemic toxicity, No
chronic toxicity.
· Hemocompatibility of outer layer of the device
12. The device and its components shall not degrade within the body, thus preventing
immune system responses and generation of small particle disease.
13. The device shall not induce scar formation due to friction or irritation of any of
the surrounding tissues, such as the vessel endothelium, the epicardium,
myocardium, and endocardium, and the visceral layer of the pericardium.
14. The device shall not induce hyperplasia, hypoplasia or hypertrophy in any of the
surrounding tissues, such as the vessel endothelium, the epicardium, myocardium,
and endocardium, and the visceral layer of the pericardium.
Physiological Requirements
15. The device shall not interfere with heartbeat rhythm.
16. The device shall not form pressure on surrounding tissues and organs.
The device preliminary concept of design and main components are illustrated in
Figure 2, 3, and 4 herein.
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Figure 2 - The EM device is mounted on the stent
Blood
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Coils
Figure 3 - A cross-sectional view of the EM device
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Figure 4 - System Concept. RFID Tag facilitates wireless communication with
External reader.
5.3 Design and Implementation
5.3.1 Design Concept
The device will be incorporated within an arterial coronary stent.
In order to measure flow the device shall utilize one of the following techniques:
1. Electromagnetic induction (EM prototype) - based on Faraday's Law, an initial
electric field within the stent, induced by an external electromagnetic field, will be altered
by the blood flow which is a conductive fluid and will cause a voltage gradient across the
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blood vessel. Thus flow characteristics will be deduced by applying an electromagnetic
field to a coil of wire adhered to the stent, and then measuring the voltage across the loop,
which is proportional to the blood flow velocity through the stent.
2. Thermodilution (TD prototype) - based on Thermodilution Laws, a constant
heating of a thermistor adhered to the stent wire mesh, induced by an external
electromagnetic field, will be altered by the blood flow which facilitates rapid dissipation
of heat off the thermistor and into the blood stream. Thus flow characteristics will be
deduced by measuring, after a time shift from initial heating, the thermistor resistance
which is proportional to the thermistor temperature. The thermistor temperature is in turn
proportional to the blood flow velocity through the stent.
Either measurement, indicative of the flow velocity through the stent, will then be
transmitted by the device wirelessly to the external reader, by utilizing a wireless
communication such as RFID technology.
Other techniques and especially ultrasound-based techniques such as Doppler-
Shift flowmeters and Transit Time flowmeters were excluded based on preliminary
estimates of power consumption that were reasonably higher than the proposed
techniques.
In order to simplify the initial development process a simple design was chosen.
Thus, the first generation device will be a 'passive' sensor - it will only measure blood
flow 'upon request', meaning upon temporarily activation from outside the body. The
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measurements will be initiated from outside the body by an external reader that will
power the device and stimulate its components to produce flow measurement and related
readings that can be directly correlated to a fluid velocity and flow rate. This will be
done through an electromagnetic process of induction and will allow the device to
perform without a self electrical power source, eliminating the need to implant a battery,
and thus eliminating associated risks. Furthermore, the first generation of this device will
incorporate unidirectional data transfer to only signal the flow measurement outside of
the body to be received by the external reader.
Future generations would potentially allow data storage of blood flow 'upon
defined events', requiring an internal electrical power source, and would potentially
incorporate bidirectional data transfer - to allow both inward communications, to allow
control, initiation and calibration of the device, and outward communications, to allow
signaling the flow measurement to the external reader.
5.3.2 Sub Components
In order to fulfill its required functionality, the device shall consist of the
following major components (see Table 3 for details):
1. Silicon-coated Chip
The Chip shall provide the support frame for all of the device components. The
Chip shall be made of unalloyed, grade 2 titanium (ASTM B-338-95; Tico Titanium,
Inc., Farmington Hills, MI). This material was chosen as the substrate for the Chip based
on its long history of use the cardiovascular experimentation. The entire surface of the
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Chip will be coated with Silicon to ensure biocompatibility, and to avoid friction or
pressure on surrounding tissues while arterial contraction and dilation.
2. Electrical Source
The device will have no internal electrical power source - its operation will be
initiated from outside the body by an external reader that will power the device and
stimulate its components through an electromagnetic induction.
3. Measuring Element
a. EM prototype - Coils will serve as the flow measurement electromagnetic
sensor, to actually measure a momentarily blood flow through the stent. The coils shall be
made of a conductive, biocompatible metal. Preliminary choices would be either
tungsten or gold, based on current findings which suggest that even if the tungsten
corrodes, cell function is not affected4 7.
b. TD prototype - A thermistor adhered to the stent wire mesh will be heated by
a point heater. The thermistor resistance after a time shift from initial heating, which is
proportional to the thermistor temperature, which is in turn proportional to the fluid
velocity through the stent, will be measured to deduce blood flow velocity through the
stent.
4. Data Processing
Analog measurement of voltage will be converted to digital signals by using an
A/D converter located on the Chip.
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5. Communication
A RFID tag shall facilitates wireless communication of the digital signal between
the device and the external reader using radio frequency waves. The tag consists of an
integrated circuit to encode and hold information (specific identification code, and
voltage gradient parameter). The stent wire mesh would serve as the tag antenna to
transmit data to the external reader. The tag profile will be attached to the Chip.
The first generation device will include a 'Passive tag', which derive its energy
from radio frequencies generated by the external reader and do not require a self
electrical power source, and therefore are much smaller and less expensive compared to
'Active tags', which do require an internal power source. A characteristic radio frequency
initiated by the external device, shall induce electrical current in the antenna and the tag
shall reflect back its identification code and a voltage gradient parameter.
The RFID tag shall operate low frequency radio waves of 125-134 KHz.Low
frequency waves, while limiting the read range potential to around 1.5 meters, will
demonstrate the following advantages:
· Works well near metal, such as the Stent and Coils
· Does not affect human tissues
· Does not induce heart electrical stimulation of interfere with heartbeat
Currently, 'Passive tags' are commercially available and are manufactured to well
defined engineering specifications, defined as Class 0 or Class 1 in North America.
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The smallest such devices are measured 0.4 mm x 0.4 mm, and cost from US$0.40. The
134.2 kHz RFID chips, from VeriChip Corp., a subsidiary of Applied Digital Solutions
Inc., was recently approved by the FDA to be the first RFID chips that can be implanted
in humans.
6. External reader
The external reading device will be designed as a handset and serve a number of
functions. The external device shall place an electromagnetic field across the body to
power the device, by stimulating a current in the coils to create the local magnetic field
and by activating the RFID tag to sense and transmit the vessel voltage gradient.
Readings of voltage gradient shall be directly correlated to a fluid velocity and flow.
The external reader shall operate low frequency radio waves of 125-134 KHz, to
demonstrate the same advantages as the RFID tag.
The external reader shall consist of an antenna packaged with a transceiver and
decoder, to decode the data encoded in the tag's chip, present it as a fluid flow parameter
and send the data to a host computer for processing.
Component Prototype Beta version
Electrical Source Power Supply External
Measuring EM prototype: MicroChip elements
Element 1. Electrodes - Copper tape
2. Wire - 30 AWG Wire
TD prototype:
1. Thermistors (GE. Edison, NJ,
US)
2. Resistive Wire (JLC Eletromet.
RI, US)
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Data Processing Digital Multimeter (John Fluke, A/D Converter
WA, US)
Transmission NA RFID tag
Receiving NA Receiver
Table 3 - Component Breakdown
5.4 Value Proposition
The device will provide a significant improvement in standard of care and quality
of life for patients suffering from ischemic vascular disease, and would improve
diagnosis and end results of related treatment administration by allowing physicians to
monitor the success of ongoing treatments between surgery and stenosis. The device will
offer many advantages compared to current techniques, including:
For Physicians -
· Implanted during existing procedure - easy adoption
· Allows intra and post operative dynamic monitoring
* Allows a longitudinal surveillance of each stent performed
* Reliable and reproducible results
* Ease of use, rapidly performed readings
* Allows a lengthwise study along the stent (by placing and reading from
multiple devices placed in different locations on a single stent)
For Patients -
· Peace of mind
* Early detection of restenosis allowing earlier, safer and more effective
intervention - to improve outcome and reduced mortality of occlusions
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For
* No documented side-effects of related materials
* Non-invasive measurements - avoid risks of invasive procedure
3rd Party Payers and Hospitals -
· Cost effectiveness - inexpensive surveillance
* Out-patient clinical readings
* Earlier, safer and more effective intervention - fewer re-operati(
· Improved standard of care
)ns
The utilization of the proposed device may provide a new, superior diagnostic
tool within existing implantable devices - such as the coronary stent, allowing earlier,
more efficient intervention, thus further reducing patients' risk, improving clinical
outcome, and reducing cost to society4 8 .
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6 Feasibility Assessment
6.1 In-vitro Experiment
6.1.1 Overview
The purpose of the In vitro experiment is to demonstrate a proof-of-concept for
the proposed approach as a mean to monitor flow rate within a stented vessel.
A Stented Coronary Artery (SCA) model was constructed to host the coronary stent and
the device.
Three prototypes of the device were constructed to be used in this experiment,
each utilizing a different technology to monitor flow rate - either EM or TD (see Figure
6). Each prototype was incorporated within a coronary stent deployed within the SCA
model.
A flow apparatus was constructed to provide a controlled setup for measuring
flow rate within a stent by generating fluid flow through the SCA model, thus partially
mimicking the coronary artery blood flow.
The scope of this preliminary experiment was the ability to measure flow rate
through a stented vessel. Both prototypes represent an initial, limited design of the
measurement unit of such a device, and therefore do not encapsulate all desired
components and features. Miniaturization of the device, as well as external power
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induction, and wireless communications were not represented in these prototypes and
were accounted for by other means as described later on.
6.1.2 Materials and Method
In vitro Stented Coronary Artery (SCA) model
A simplified planar model of a Coronary Artery was fabricated from a paper
straw with diameter of 4mm (Chenille-Kraft-Company, IL, USA). This represents the
diameter of a normal non-diseased LM coronary artery, which is 4.5 ± 0.5 mm in men
and 3.9 0.4 mm in women49 . The angulations and tortuosity of the Coronary Artery
segment were not reproduced.
The stent used was a commercial coronary stent (ACS Multi-Link RX Tristar 3.0
x 18mm Coronary Stent System, Guidant, Advanced Cardiovascular Systems, Inc., CA,
USA). A metal spring substituted the actual stent in the experiments conducted as part of
this thesis..
During intravascular deployment, the stent (of diameter 3 mm when fully
expanded) is located inside the paper straw. To allow flow rate measurements and data
retrieval the straw was penetrated by thin-wire. As in clinical practice, the device was
deployed by a delivery system pressurized in 2 ATM increments until the stent is
completely expanded.
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Flow circuit
The flow apparatus served the functions of partially mimicking the coronary
artery blood flow, by providing a constant flow rate of 13.6 cc/min, which translates into
flow velocity of 1.15 cm/sec which is comparable to flow rate within coronary arteries5 °.
Pulsatile flow rate was not generated at this setup. This apparatus provided a controlled
setup for measuring flow rate within a stent.
The flow apparatus is shown in Figure 5. The inlet section into the SCA model
was a straight PVC pipe (silicone tubes) of inner diameter 5mm and length 0.3m which
incorporated a temperature-controlled reservoir, a large volume infusion pump (Deltec®
3000, Graseby Medical, Watford, UK ), and an ultrasonic cannulating flow probe (24N,
Transonic System Inc., Ithaca, NY, USA). After the SCA model fluids were collected to
a fluid container.
Flow rate was generated by the infusion pump which produced a pre-defined
steady flow rate.
The actual mean flow rates were determined by measuring the volume of fluid
collected at the container over a known time interval. The flow probe served as control to
provide an additional indication of the flow rate trough the SCA model.
For flow rate measurement with the EM prototype, the fluid was a 10% sucrose
and sodium chloride solution with conductivity comparable to that of human blood51.
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For the EM prototype measurements, a constant, linear electromagnetic field was
induced at the stented site, by placing two magnets (S1030 Square magnet, N38 Nickel,
4mm thick) at opposite locations around the SCA model at a distance of 13mm. The
electromagnetic field density, measured using a Gauss meter, was 0.192 Tesla.
SCA Model
Figure 5 - Flow circuit
Flow Measurement Device
To measure blood flow through the stent, one of three different prototypes was
adhered to the stent, and measurements were made in the following three ways:
The EM prototype - two electrodes were attached to the stent at opposite
locations along its longitudinal axis. The voltage gradient induced at these electrodes by
the local electromagnetic field generated by the two magnets was measured at fixed
interval of 30 seconds after setting a specific flow rate. Faraday's Law infers that this
voltage gradient is proportional to the fluid velocity.
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The TD prototype - a transistor was used initially to point heat the stent wire
mesh at its proximal end (upstream). The resistance level of a thermistor in contact with
the transistor was measured with no flow after a period of 60 seconds post heating, and
then again with a constant flow. This initial setup was abandoned after generating a
transient voltage and was substituted by inducing constant voltage of 12V across the
thermistor and measuring its resistance with no flow and again with a constant flow. The
thermistor resistance is proportional to its temperature, and the difference in resistance
AR is then converted into a difference in temperature AT, which is proportional to fluid
velocity.
A third prototypes was built comprising of two thermistors adhered to the stent -
one upstream with no voltage across to provide a control and another downstream with
similar functionality as described in the case of a single thermistor.
Barui
Figure 6 - Device prototypes: (a) EM prototype, (b) Single-Thermistor TD
prototype, (c) Dual-Thermistor TD prototype
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6.1.3 Results
In the present study, longitudinal velocity component was measured and
presented. Velocity measurements were made in the stented site at the locations shown in
Figure 5. Each data point represents an average of the velocity derived from 5-15
consecutive measurement cycles at a constant flow rate, with SD associated with theses
cycles. Flow rate was then calculated out of the deduced fluid velocity.
The EM prototype
Based on Faraday's law, the amount of voltage (E) developed across the
electrodes will be proportional to the diameter of the vessel (D), the magnetic field
density (B) generated by the coils, and the velocity (V) of the blood flow:
E = V x B x D (where B=0.192 Tesla and D=Smm)
As B and D are known in this setup (which in this case will be the local magnetic
field and the distance between the electrodes, respectably), the fluid velocity V can be
easily deduced by measuring E, and is given by m/sec units. V is then converted into
cm/min units to comply with flow rate units.
Flow Rate is calculated by:
Flow Rate = Fluid Velocity * Lumen Area
Lumen Area is given by r2 and in this setup where r=2.5mm the area equals
0.19635cm 2 .
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Two sets of measurements were conducted, in which the average flow rate
calculated were 13.13 cc/min and 54.14 cc/min and the measurement standard deviation
were 0.47 and 21.64 respectably (see Table 4 for detailed results). The voltage across the
electrodes with no flow, which served as a control, was zero.
First measurement - mean
No. Actual Flow E V V Calculated Flow
rate Voltage after 30 Fluid Velocity Fluid Velocity Rate (cc/min)
(cc/min) sec with flow (m/sec) (cm/min)
(mV)
1. 13.6 88.76 0.0108 64.89 12.74
2. 13.6 86.16 0.0111 66.85 13.13
3. 13.6 85.70 0.0112 67.21 13.20
4. 13.6 89.02 0.0108 64.70 12.70
5. 13.6 81.55 0.0118 70.63 13.87
Second measurement
No. Actual Flow E V V Calculated Flow
rate Voltage after 30 Fluid Velocity Fluid Velocity Rate (cc/min)
(cclmin) sec with flow (m/sec) (cm/min)
(mV)
6. 13.6 19.55 0.0491 294.63 57.85
7. 13.6 17.92 0.0536 321.43 63.11
8. 13.6 36.09 0.0266 159.60 31.34
9. 13.6 13.50 0.0711 426.67 83.78
10. 13.6 32.65 0.0294 176.42 34.64
Table 4 - EM prototype - results of first and second measurements
The TD prototype
Based on Thermodilution laws, the heat conduction for a spherical heating
element of radius a in an infinite medium with no flow can be modeledt:
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JH= -kVT = kVz where TT
Heat Flux ( JH) equals the product of thermal conductivity (k) and temperature
gradient ( VT), and r is the difference in temperature at a location in the medium (T) and
at an infinity (T).
In steady state V JH = 0 > V2 = 0. The solution for r in the case of
spherical symmetry is r = ,s where r is the radial distance from the origin at the
r
center of the sphere and r s is the temperature at the surface of the sphere . Therefore for
4xlxr2 xkxz xa
the heat conduction: J= 4 X H = 
or Q'=4xflxkxrs xa
In this setup, where kwate=0.0016 22 cal/cm*s*°C, s is approximately 1°C, and
a= mm, Q'= 0.0144 Watts. Solving for rs we obtain a value of 1.7°C which is in good
ballpark agreement with our observations (-1°C) in the no flow states given the very
different geometry of our set up.
As for heat conduction under dynamic flow conditions, that involves complex
thermodynamic algorithms and would require a computer simulation and building an
empirical model to take into account the specific setup and dynamics. For the scope of
this thesis, the fact that the measured AT comparing the flow and no flow states is quite
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consistent across different measurements suggest that such simulation and empirical
model can be further developed to accurately deduce fluid velocity.
One set of measurements was conducted for the single-thermistor prototype, in
which the difference in resistance and deduced temperatures across the thermistor with
and without flow were measured (see Table 5 for detailed results).
Single Thermistor
No. Actual Current Current R AT
Flow rate (mA) after (mA) after Resistance (°C)
(cc/min) 60 sec 60 sec (0)
heating heating
with water with flow
1. 13.6 1.218 1.199 155.47 0.35824
2. 13.6 1.154 1.135 173.35 0.37547
3. 13.6 1.157 1.138 172.44 0.37463
4. 13.6 1.170 1.148 195.73 0.43007
5. 13.6 1.171 1.153 159.31 0.35108
6. 13.6 1.181 1.163 156.61 0.34849
7. 13.6 1.189 1.170 163.21 0.36577
8. 13.6 1.232 1.197 283.62 0.65786
9. 13.6 1.196 1.156 345.73 0.77219
10. 13.6 1.177 1.154 202.35 0.44745
11. 13.6 1.189 1.163 224.69 0.5019
12. 13.6 1.183 1.162 182.56 0.40643
13. 13.6 1.188 1.165 198.59 0.44383
14. 13.6 1.187 1.169 155.02 0.34696
Table 5 - TD prototype - results of single-thermistor measurements
Additional set of measurements was conducted for the dual-thermistor prototype,
in which both downstream thermistor and the upstream control thermistor temperature
differences were measured (see Table 6 for detailed results).
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Dual Thermistor - Downstream
No. Actual Current Current LR AT
Flow rate (mA) after (mA) after Resistance (°C)
(cc/min) 60 sec 60 sec (n)
heating heating
with water with flow
1. 13.6 1.289 1.249 296.90 0.72304
2. 13.6 1.259 1.219 311.46 0.73814
3. 13.6 1.239 1.210 231.16 0.54062
4. 13.6 1.243 1.222 165.21 0.38927
5. 13.6 1.237 1.217 158.76 0.37210
6. 13.6 1.257 1.218 304.40 0.72044
7. 13.6 1.261 1.221 310.45 0.73712
8. 13.6 1.252 1.220 250.35 0.59175
9. 13.6 1.256 1.222 264.72 0.62741
10. 13.6 1.258 1.234 184.75 0.44071
Dual Thermistor - Upstream Control (power applied to downstream thermistor)
No. Actual Resistance Resistance AR AT
Flow rate (KG) after (KG) after Resistance (°C)
(cc/min) 60 sec 60 sec (n)
with water with flow
11. 13.6 11.056 11.190 0.134 0.27014
12. 13.6 11.315 11.415 0.1 0.19671
13. 13.6 11.398 11.417 0.019 0.03721
14. 13.6 11.422 11.390 -0.032 -0.06271
15. 13.6 11.360 11.419 0.059 0.1158
16. 13.6 11.307 11.398 0.091 0.17925
17. 13.6 11.247 11.367 0.12 0.23747
18. 13.6 11.313 11.374 0.061 0.12027
19. 13.6 11.398 11.371 -0.027 -0.05302
20. 13.6 11.572 11.290 -0.282 -0.5512
Table 6 - TD prototype - results of dual-thermistor measurements
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6.2 Interpretation of Results
All prototypes were shown to enable the interpretation of flow velocity. However,
the observed results, as well as several technical obstacles that were encountered along
the way, give rise to important technical considerations.
These considerations might affect factors such as the required setup, the
calibration process and the repeatability of measurements and must, therefore, be taken
into account when evaluating the best approach for an implantable device.
The EM prototype posed several technical difficulties, which would disfavor
utilizing this approach in an implanted device.
The voltage measurements across the electrodes fluctuated when the electrodes
were placed such that they contacted the stent wire mesh. This is believed to be due to
circuit shortage conducted by the mesh itself. In addition, this approach requires that the
electrodes would be in contact with the fluid itself, to measure voltage gradient across the
vessel lumen. However, such direct contact mode is not guaranteed in-vivo when the
stent is coated with endothelium cells or plaque, in the case of restenosis. This would
require an undesired post-procedure calibration involving a catheter as a reference scale.
Another technical uncertainty relates to the external magnetic field induced to
allow the measurement - varying orientation and distance of the external device relative
to the implanted device would reduce the repeatability and accuracy of the
measurements. While this variation can be compensated by certain constrains such as
external reader design, it increases system complexity and pose limitation on the
operator.
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The TD prototype seems to facilitate a more comprehensive approach,
independent of external reader properties. However, several feasibility issues should be
considered in this approach as well.
The initial design comprising of a transistor as a heating element and a thermistor
as the measurement element, generated a transient voltage increase at each measurement.
The transient voltage is believed to be due to convection flow resulting of the point
heating technique used. To eliminate this transient voltage, different approaches was
tested - to directly heat the thermistor and measure its resistance after a predefined time
period - and indeed the transient voltage was not observed.
The use of two thermistors provided a less accurate measurement of flow
velocity, probably due to the downstream location of the measurement element. The
upstream control element maintained its emperature. This dual setup can be advantageous
in vivo to compensate for different blood temperature in different physiological
conditions without recalibration, but on the other end contributes increased technical
complexity and requires additional hardware incorporated within the stent.
The accuracy and repeatability in the presence of a coated stent with either
endothelium or plaque of varied composition is yet another uncertainty which should be
evaluated in further in-vitro and in-vivo studies.
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7 Critical Assessment of Own Work
7.1 Significance
In previous sections of this work I have demonstrated a sufficient clinical
ambiguity and a vibrant controversy regarding the use of stents, especially DES,
following angioplasty in ischemic arterial beds. This use is limited by complications and
continuing vascular deterioration. My findings, both in a literature survey and a
preliminary questionnaire answered by specialists dealing with patients suffering
ischemic arterial beds, suggest that there is a clear clinical need, well defined and highly
diffused within the medical community in regards with the importance of such
monitoring as well as the short reaching of existing modalities in addressing this need.
There is a broad agreement of the parameter which is most indicative of vessel patency -
flow rate through the stent, and a shared anticipation that monitoring this parameter might
change standard of care and improve clinical outcome.
While further, more comprehensive and of larger scale studies should be complete
to better gauge and quantify the potential market - market economics such as potential
demand, margins, price points, and growth drivers, market mechanics such as channels,
barriers to entry and power distribution, and other important factors - the findings
described herein are encouraging enough to support the Hypothesis that there exists a
market for a novel approach facilitating monitoring of vessel patency post procedure.
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7.2 Feasibility
Previous sections of this work have described multiple available techniques to
enable the in-vivo measurement of blood flow rate through a stent, to establish vessel
patency and the need for treatment adjustment or reintervention, as a real-time, wireless,
and non-invasive monitoring paradigm.
The proposed approach address, in theory, various requirements and design consideration
to enable the development and assembly of a novel device that would address the clinical
need identified.
While further development is required to mitigate technical uncertainties and
comply with physiological and biological requirements, a proof of concept was
demonstrated by building a prototype and running an in-vitro experiment. Although
simple and limited, the preliminary results of that experiment have shown that the
fundamental concept is feasible and that flow rate can be measured at the stent
intraluminally.
Next developmental steps to achieve miniaturizing, external power induction, and
wireless communication - are all based on proven technologies which have been
demonstrated in practice in multiple other applications. Therefore I believe the findings
described in this work sufficiently support the Hypothesis that such a device can be
designed and built.
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8 Work Provision
8.1 Market Application
The market for coronary stents and drug-eluting stents in particular is the leading
stent market at approximately $5 billion annually and predicted to maintain its growth.
This is therefore the most lucrative market application for the proposed approach
discussed in this thesis.
However, additional in-vivo applications exist, which would potentially be
enhanced by the proposed approach, providing physicians the means to monitor patency
and flow rate in a non-invasive method - the use of stents in other parts of the body, such
as carotid stents, vascular stents in the lower extremities, and biliary stents, is rapidly
expanding both in clinical indications and in volume of procedures. Additional candidate
modalities include vascular grafts, both native and synthetic52, and shunts, such as
Cerebrospinal Fluid shunts (CSF) to treat high intracranial pressure, and Transjugular
Intrahepatic Portosystemic shunts (TIPS) to treat high blood pressure in the liver.
Extensive market research should be conduct to quantify the potential of each
application, but the following factors should be considered as a first step to validate the
fit for a specific application 53:
* Clinical need - How important is patency/flow rate monitoring? What is the level
of susceptibility to narrowing/blockage?
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· Uniqueness - Are there any other modalities to monitor patency/flow rate in the
specific location/device?
· Feasibility - What accuracy level would the proposed approach achieve? What
would it take to incorporate the proposed approach in the modality?
· Ease of use - Would the proposed approach allow a simple, quick measurement?
· Resistance - What proof of efficiency is required to facilitate adoption? Are there
external factors that would limit the use/adoption of the proposed approach?
Carotid stents, vascular stents in the lower extremities would pose a lower
technical challenge - by allowing a larger device due to the wider vessel lumen, and also
by providing a more 'friendly' environment - with minimal vessel movement and more
adjacent to the skin - which can improve measurement accuracy. However, other
modalities and especially ultrasound can nearly fulfill the clinical need and therefore the
uniqueness of the proposed approach is less vivid.
CSF shunts and TIPS would also pose lower technical constraints, they are highly
susceptible to blockage requiring their replacement, and there is no available technique to
monitor their patency. However, the flow rate in these shunts is very slow compared to
the rate in coronary arteries, and therefore a different measurement technique might be
required to fulfill that need.
Synthetic grafts might be a good candidate to start with, as the incorporation of
the proposed measurement device is quite straight forward, and there is no other modality
to monitor graft patency. However, the market trend in the last few years was definitely
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towards using more non-invasive catheter-delivered stents than bypassed grafts requiring
an open chest surgery.
In general, it seems as if a strategy of targeting first a lower hanging fruit such as
synthetic vascular grafts or lower extremities vascular stents would be a favorable
approach and allow delivering a simpler product quicker, deepen technical knowledge
and expertise and gain market feedback. This would facilitate easier adoption and earlier
success that would allow then targeting the much more lucrative market of coronary
stents.
8.2 Commercialization
The project has past the stage of formulating the general design concept of such a
device and identifying its main components and material involved, and is currently at the
stage of developing a proof-of-concept prototype to be tested and verified both in-vitro
and in-vivo on animal model. For Class III device key next steps after developing a
proof-of-concept prototype, and running initial animal trials, would probably require
some long-term animal implant studies before proceeding into human trials and a FDA
PMA clearance process. These steps will be facilitated by sponsored research support and
later on by venture financing. The process of filing for a conceptual patent has started in
order to secure IP issues.
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8.3 Risk Mitigation
Potential technical uncertainties include efficacy and reliability within the body.
The device should be miniaturized utilizing MEMS technology and demonstrate in-vivo
efficacy. The development of a proof-of-concept fully functional device prototype and
the initial animal studies will clarify technical uncertainties. In order to mitigate the
technical risk, all candidate technologies involved have been demonstrated to
successfully measure flow in similar applications with somewhat different settings.
Potential clinical uncertainties include safety and biocompatibility within the
body. Being incorporated within a coronary stent, intraluminally, the device poses a risk
of thrombosis or tissue deposition or encapsulation due to potential fibrotic reactions on
its surface. The minimal footprint, <0.5mm3, as well as the coated silicon should mitigate
these risks. In order to mitigate the biocompatibility risk, all the materials which are to be
used to compose the device components are well documented and are currently used
extensively in the human body including cardiac defibrillators, pace makers and artificial
vascular grafts with little or no immune response.
Potential market uncertainties include adoption rates and competing non-invasive
imaging techniques. Immediate next step would be to conduct an initial primary market
research to reduce market uncertainties. In order to facilitate rapid adoption the project
team has started building meaningful close relationships with luminaries and thought
leaders within the medical community, and specifically with cardiac and vascular
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surgeons, and an on-going field feedback will be maintained through the entire
development and clinical studies. Non-invasive imaging techniques are still decades
away from reaching the required sensitivity and specificity.
8.4 Impact
Commercial - The introduction of such a device into the medical device market
will have a significant commercial effect. It will improve the efficacy and capabilities of
the healthcare system - while enhancing best practice surveillance and treatment of post
surgery patients; it will have a much broader impact on the specialty of interventional
cardiology, as well as other specialties, by facilitating a non-invasive, ongoing
monitoring and blood analysis of various relevant hematological factors.
Taking advantage of its non-invasive, simple-to-conduct nature, physicians across the
country will be able to conduct precise, fast analysis of restenosis status and progress
over time, by simply reading flow values at interest sites, and would potentially improve
end results of related treatment administration. Accordingly, such a device will be
adopted by the community of interventional cardiologists. As no other comparable device
exists to date, it is clear that there will be a significant commercial benefit associated.
Societal - I believe that this technology and its successful commercialization will
have a far-reaching societal impact. As described previously, there is currently no
available technology for detection of stent occlusion post surgery. The first sign that
something is wrong is when the stent is nearly completely blocked, at which stage
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interference is usually impossible and this is frequently a fatal occurrence. I believe that
this technology will widen the number of early diagnosed patients as undergoing a
restenosis progress; offering hope for patients who would only be diagnosed and treated
much later with today's capabilities, thus reducing the number of patients requiring
repeated intervention or suffering severe adverse events and saving tens of thousands of
lives annually. In addition, the device will allow surveillance and sequential treatment
that will offer a radical improvement in quality of life and peace of mind for these
patients through earlier and more efficient treatment. Various resources, first and
foremost human resources, will be freed up to address other medical challenges, increase
society's productivity, and significantly reduce health related costs.
Educational - This commercialization effort will advance the education of
physicians nationwide. As there are no competing devices available, there is a huge
potential for research which has been heretofore impossible - by revealing and
quantifying the ongoing progress of restenosis and fibrosis and compare this progress
outcome in the presence of various treatments and medications the effect of medication
on flow could be directly studied. Additional questions, such as how does flow change
with exercise, and does the loss of normal capacity for such change constitute an early
indication of trouble can be answered. The technology opens whole new areas of
investigation, and it is expected that thought leaders and luminaries who will be involved
in utilizing this technology will develop new medical techniques and best practices to be
adopted by the rest of the medical community.
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9 Summary Conclusion
In this thesis, I have explored and tested the Hypotheses that there is a market
for a direct, non-invasive monitoring of vessel patency at the site of a coronary stent;
and that an implantable, wireless, stent-based device to monitor blood flow rate
through a coronary stent can be designed and built.
A literature survey of late clinical studies regarding the safety and efficacious of
DES reveals sufficient clinical ambiguity to justify the proposed approach. Results of
interviews and preliminary questionnaire with numerous specialist clinicians portrait an
underserved clinical need and further justify the introduction of a direct, non-invasive
modality for monitoring of vessel patency at the site of a coronary stent as part of the best
practice follow-up regimen. Although no comparable modality exists, clinicians were
unanimously positive about welcoming the proposed approach and certain that such a
tool has the potential to improve clinical outcome. The practitioners' interest, therefore,
seems to be clinically driven.
A research of related techniques and existing intellectual property establish the
notion that measurement techniques are available for monitoring of vessel patency at the
site of a coronary stent. Preliminary results of an in-vitro experiment with a prototype
that was built as part of this project demonstrate partial proof-of-concept and together
with emerging technologies such as MEMS and wireless communication techniques
place the foundations for designing and developing a stent-based, implantable, and
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wireless device that would allow a direct, non-invasive efficacious measurement of blood
flow rate through coronary stents.
While not in the scope of this thesis project, additional potential applications for
such an approach are far more reaching than coronary stents and might as well position
this technique as a platform technology for numerous clinical applications.
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